大鼠骨癌痛模型的建立及其脊髓GFAP表达水平的变化
|
摘要
目的
采用Walker 256大鼠乳腺癌细胞建立大鼠胫骨癌痛模型,并验证模型建立的成功,建立大鼠慢性炎症及神经病理性疼痛模型并与骨癌痛模型进行疼痛行为学比较。用免疫组织化学实验(IHC)观察三种疼痛模型大鼠脊髓神经胶质纤维酸性蛋白(GFAP)表达水平的变化。
方法
将36只SD雌性大鼠,随机分为4组:①肿瘤组(Sarcoma n=8):接种肿瘤细胞;②假手术1(Shaml n=10):接种不含肿瘤细胞的大鼠腹水;⑧假手术2(Sham2 n=10):接种生理盐水;④正常对照组(Naive n=8)。参照Medhurst等报道的方法将含1×10~5Walker 256大鼠乳腺癌细胞悬液注入大鼠胫骨上段制备骨癌痛模型。Sham 1和Sham 2分别注入等体积的不含肿瘤细胞的大鼠腹水和生理盐水,观察疼痛行为学(一般情况、体重、机械缩足反射阈值MWT和热缩足潜伏期PWTL)、骨放射学和组织学。同样规格大鼠52只,随机分为6组:①慢性炎症疼痛模型(CFA,n=10),注射CFA;②假手术组(NS,n=8):注射NS;③坐骨神经部分结扎模型(PNL,n=9);④假手术组(Sham,n=9);⑤⑥正常对照组(Naive n=8);观察大鼠疼痛行为学。三种疼痛模型及其对照组分别在疼痛高峰期间处死取脊髓标本,冰冻切片后行免疫组化,观察三种模型大鼠脊髓GFAP表达水平的变化。
结果
从疼痛行为学、影像学、组织学多方面观察的结果证实,Walker 256大鼠乳腺癌细胞能成功制备大鼠胫骨癌痛模型。Sarcoma组造模后第7天开始体重不增或降低、MWT显著降低(P＜0.01),第11天PWTL显著降低(P＜0.01)。疼痛高峰期间,三种疼痛模型中CFA大鼠MWT最低(P＜0.01),Sarcoma组和PNL组无明显差异(P＞0.05),三种疼痛模型PWTL无明显差异(P＞0.05)。Sarcoma和PNL大鼠脊髓GFAP的上调水平高于CFA、Sham及Naive组(P＜0.01);Sarcoma组脊髓GFAP的上调水平高于PNL组;且统计学上有显著差异(P＜0.05)。CFA大鼠脊髓GFAP表达水平与NS组相比无明显差异(P＞0.05)。
Objective
The aim of this investigation was to set up tibial cancer pain model with Walker 256 mammary gland carcinoma cells in rats,and compare differences of painful behaviors with inflammatory & neuropathic pain model.GFAP that has been implicated in the generation and maintenance of chronic pain was then examined in spinal cord by IHC method and evaluated whether its expression was different in three chronic pain models.
Methods
36 female SD rats were randomly divided into 4 groups:①Sarcoma(n=8,tumor cells were injected);②Sham1(n=10,rat ascetic fluid without tumor cells was injected);③Sham 2(n=10,NS was injected);④Na(i|¨)ve(n=8).According to the method described by Medhurst et al,10~5 syngenenic Walker 256 mammary gland carcinoma cells,ascetic fluid without tumor cells and NS were respectively injected into the tibia medullary cavity via intercondylar eminence.Series of tests were carried out including general condition,weight bearing ability,ambulatory pain,MWT,PWTL together with bone radiology and bone histology.Another 52 female SD rats were randomly divided into 6 groups:①CFA(n=10);②NS(n=8);③PNL(n=9);④Sham(n=9);⑤⑥Na(i|¨)ve(n=8), and underwent as above.All rats were sacrificed at the period of remarkable pain.GFAP was then examined in spinal cord by IHC method and evaluated whether its expression was different in three chronic pain models.
Results
Rats that developed of hyperalgesia and allodynia after intra-tibial injection of Walker 256 cells were proved successful.MWT and PWTL were measured during the experimental days,and the findings revealed Sarcoma rats started to exhibit mechanical allodynia on the 7~(th) day and thermal hyperalgesia on the 11~(th) day after the operation(P＜0.01).At the period of remarkable pain,CFA rats exhibited mechanical allodynia stronger than Sarcoma and PNL rats(P＜0.01),but no difference was observed between Sarcoma and PNL rats(P＞0.05).The difference of thermal hyperalgesia between three chronic pain models was not remarkable(P＞0.05).The up-regulation of GFAP expression in spinal cord of Sarcoma rats was significantly greater than that induced by PNL(P＜0.05) and CFA(P＜0.01) model.The up-regulation of GFAP in PNL model was significantly greater than that induced by CFA model(P＜0.01).Compared to Sham or Na(i|¨)ve group, no change of GFAP was observed in the spinal cord of CFA.The data suggests that the mechanisms of bone cancer pain are complicated and different from inflammatory and neuropathic pain.
采用Walker 256大鼠乳腺癌细胞建立大鼠胫骨癌痛模型,并验证模型建立的成功,建立大鼠慢性炎症及神经病理性疼痛模型并与骨癌痛模型进行疼痛行为学比较。用免疫组织化学实验(IHC)观察三种疼痛模型大鼠脊髓神经胶质纤维酸性蛋白(GFAP)表达水平的变化。
方法
将36只SD雌性大鼠,随机分为4组:①肿瘤组(Sarcoma n=8):接种肿瘤细胞;②假手术1(Shaml n=10):接种不含肿瘤细胞的大鼠腹水;⑧假手术2(Sham2 n=10):接种生理盐水;④正常对照组(Naive n=8)。参照Medhurst等报道的方法将含1×10~5Walker 256大鼠乳腺癌细胞悬液注入大鼠胫骨上段制备骨癌痛模型。Sham 1和Sham 2分别注入等体积的不含肿瘤细胞的大鼠腹水和生理盐水,观察疼痛行为学(一般情况、体重、机械缩足反射阈值MWT和热缩足潜伏期PWTL)、骨放射学和组织学。同样规格大鼠52只,随机分为6组:①慢性炎症疼痛模型(CFA,n=10),注射CFA;②假手术组(NS,n=8):注射NS;③坐骨神经部分结扎模型(PNL,n=9);④假手术组(Sham,n=9);⑤⑥正常对照组(Naive n=8);观察大鼠疼痛行为学。三种疼痛模型及其对照组分别在疼痛高峰期间处死取脊髓标本,冰冻切片后行免疫组化,观察三种模型大鼠脊髓GFAP表达水平的变化。
结果
从疼痛行为学、影像学、组织学多方面观察的结果证实,Walker 256大鼠乳腺癌细胞能成功制备大鼠胫骨癌痛模型。Sarcoma组造模后第7天开始体重不增或降低、MWT显著降低(P＜0.01),第11天PWTL显著降低(P＜0.01)。疼痛高峰期间,三种疼痛模型中CFA大鼠MWT最低(P＜0.01),Sarcoma组和PNL组无明显差异(P＞0.05),三种疼痛模型PWTL无明显差异(P＞0.05)。Sarcoma和PNL大鼠脊髓GFAP的上调水平高于CFA、Sham及Naive组(P＜0.01);Sarcoma组脊髓GFAP的上调水平高于PNL组;且统计学上有显著差异(P＜0.05)。CFA大鼠脊髓GFAP表达水平与NS组相比无明显差异(P＞0.05)。
Objective
The aim of this investigation was to set up tibial cancer pain model with Walker 256 mammary gland carcinoma cells in rats,and compare differences of painful behaviors with inflammatory & neuropathic pain model.GFAP that has been implicated in the generation and maintenance of chronic pain was then examined in spinal cord by IHC method and evaluated whether its expression was different in three chronic pain models.
Methods
36 female SD rats were randomly divided into 4 groups:①Sarcoma(n=8,tumor cells were injected);②Sham1(n=10,rat ascetic fluid without tumor cells was injected);③Sham 2(n=10,NS was injected);④Na(i|¨)ve(n=8).According to the method described by Medhurst et al,10~5 syngenenic Walker 256 mammary gland carcinoma cells,ascetic fluid without tumor cells and NS were respectively injected into the tibia medullary cavity via intercondylar eminence.Series of tests were carried out including general condition,weight bearing ability,ambulatory pain,MWT,PWTL together with bone radiology and bone histology.Another 52 female SD rats were randomly divided into 6 groups:①CFA(n=10);②NS(n=8);③PNL(n=9);④Sham(n=9);⑤⑥Na(i|¨)ve(n=8), and underwent as above.All rats were sacrificed at the period of remarkable pain.GFAP was then examined in spinal cord by IHC method and evaluated whether its expression was different in three chronic pain models.
Results
Rats that developed of hyperalgesia and allodynia after intra-tibial injection of Walker 256 cells were proved successful.MWT and PWTL were measured during the experimental days,and the findings revealed Sarcoma rats started to exhibit mechanical allodynia on the 7~(th) day and thermal hyperalgesia on the 11~(th) day after the operation(P＜0.01).At the period of remarkable pain,CFA rats exhibited mechanical allodynia stronger than Sarcoma and PNL rats(P＜0.01),but no difference was observed between Sarcoma and PNL rats(P＞0.05).The difference of thermal hyperalgesia between three chronic pain models was not remarkable(P＞0.05).The up-regulation of GFAP expression in spinal cord of Sarcoma rats was significantly greater than that induced by PNL(P＜0.05) and CFA(P＜0.01) model.The up-regulation of GFAP in PNL model was significantly greater than that induced by CFA model(P＜0.01).Compared to Sham or Na(i|¨)ve group, no change of GFAP was observed in the spinal cord of CFA.The data suggests that the mechanisms of bone cancer pain are complicated and different from inflammatory and neuropathic pain.
引文
1. Medhurst, S.J., et al., A rat model of bone cancer pain. Pain,2002. 96(1-2): p. 129-40.
2. Portenoy RK, L.P., Management of cancer pain. Lancet,1999. 353: p. 1695-1700.
3. Meuser T, P.C., Radbruch L , et al, Symptoms during cancer pain treatment following WHO guidelines : a longitudinal follow up study of symptom prevalence,severity and etiology. Pain, 2001. 93: p. 247-257.
4. Banning, A., P. Sjogren, and H. Henriksen, Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain,1991. 45(1): p. 45-8.
5. Coleman, R.E., Skeletal complications of malignancy. Cancer, 1997. 80(8 Suppl): p. 1588-94.
6. Thurlimann, B. and N.D. de Stoutz, Causes and treatment of bone pain of malignant origin. Drugs, 1996. 51(3): p. 383-98.
7. S . Mercadante, Malignant bone pain: pathophysiology and treatment. Pain, 1997. 69: p. 1-18.
8. Pecherstorfer M, V.M., Diagnosis and monitoring of bone metastases: clinical means. In: Body JJ, ed. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, Inc, 2000: p. 97-129.
9. Preston D, B.K., Schiefelbein M, Spicer J, Palliation of painful bone metastases: radioactive isotopes. In: Body JJ, ed. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, Inc, 2000: p. 287-304.
10. Mercadante, S. and E. Arcuri, Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev, 1998. 24(6): p. 425-32.
11. Portenoy, R.K. and N.A. Hagen, Breakthrough pain: definition, prevalence and characteristics. Pain, 1990. 41(3): p. 273-81.
12. Mercadante, S., Malignant bone pain: pathophysiology and treatment. Pain, 1997. 69(1-2): p. 1-18.
13. Mercadante, S., Controversies over spinal treatment in advanced cancer patients. Support Care Cancer, 1998. 6(6): p. 495-502.
14. Portenoy, R.K., D. Payne, and P. Jacobsen, Breakthrough pain: characteristics and impact in patients with cancer pain. Pain, 1999. 81(1-2): p. 129-34.
15. Luger, N.M., et al., Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res, 2001. 61(10): p. 4038-47.
16. SD, S.M.H.P.R., Neurochemical and cellular reorganization of the spinal cord in a marine model of bone cancer pain. Neurosci, 1999. 19: p. 10886-10897.
17. al, W.P.E.m.U.R.T.e., Functional interaction between tumor and peripheral nerveFunctional interaction between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new marine model of canfer pain. Neurosci,2001. 21: p. 9355-9366.
18. Wacnik, P.W., et al., Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular Carrageenan. Pain, 2003. 101(1-2): p. 175-86.
19. Vivancos, G.G., et al., An electronic pressure-meter nociception paw test for rats. Braz J Med Biol Res, 2004. 37(3): p. 391-9.
20. Fan WK, Q.Z., Biologic characteristics of a transplantable hepatoma inbred 615 mice (H615). [A].Tang ZY. Primary Liver Cancer[M].Berlin: SpringerVerlag, Beijing: China Academic Publishes, 1989: p. 98-108.
21. Hirohashi, S., et al., Production of alpha-fetoprotein and normal serum proteins by xenotransplanted human hepatomas in relation to their growth and morphology. Cancer Res, 1979. 39(5): p. 1819-28.
22. Z . Seltzer, R.D., Y. Shir,, A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury,. Pain, 190. 43: p. 205-218.
23. Stein C, M.M., Herz A, Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol Biochem Behav., 1988 Oct. 31(2): p. 455-61.
24. Levitt, M. and J.H. Levitt, The deafferentation syndrome in monkeys: dysesthesias of spinal origin. Pain, 1981. 10(2): p. 129-47.
25. Kirk, E.J. and D. Denny-Brown, Functional variation in dermatomes in the macaque monkey following dorsal root lesions. J Comp Neurol,1970. 139(3): p. 307-20.
26. Carlton, S.M., et al., Behavioral manifestations of an experimental model for peripheral neuropathy produced by spinal nerve ligation in the primate. Pain, 1994. 56(2): p. 155-66.
27. Ford, R.W., A reproducible spinal cord injury model in the cat. J Neurosurg, 1983. 59(2): p. 268-75.
28. Hylden, J.L., et al., Descending serotonergic fibers in the dorsolateral and ventral funiculi of cat spinal cord. Neurosci Lett, 1985. 62(3): p. 299-304.
29. Butler, S.H., et al., A limited arthritic model for chronic pain studies in the rat. Pain, 1992. 48(1): p. 73-81.
30. Woolf, C.J. and R.J. Mannion, Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet, 1999. 353(9168): p. 1959-64.
31. Zimmermann, M., Pathobiology of neuropathic pain. Eur J Pharmacol, 2001. 429(1-3): p. 23-37.
32. Dornelas, C.A., et al., [Experimental model of Walker 256 carcinosarcoma in rats bladder]. Acta Cir Bras, 2006. 21(1): p. 38-42.
33. Buffon, A., et al., Diminution in adenine nucleotide hydrolysis by platelets and serum from rats submitted to Walker 256 tumour. Mol Cell Biochem, 2006. 281(1-2): p. 189-95.
1. Levitt, M. and J.H. Levitt, The deafferentation syndrome in monkeys: dysesthesias of spinal origin. Pain, 1981. 10(2): p. 129-47.
2. Kirk, E.J. and D. Denny-Brown, Functional variation in dermatomes in the macaque monkey following dorsal root lesions. J Comp Neurol, 1970.139(3): p. 307-20.
3. Carlton, S.M., et al., Behavioral manifestations of an experimental model for peripheral neuropathy produced by spinal nerve ligation in the primate. Pain, 1994. 56(2): p. 155-66.
4. Ford, R.W., A reproducible spinal cord injury model in the cat. J Neurosurg, 1983. 59(2): p. 268-75.
5. Hylden, J.L., et al., Descending serotonergic fibers in the dorsolateral and ventral funiculi of cat spinal cord. Neurosci Lett, 1985. 62(3): p. 299-304.
6. Stein C, M.M., Herz A, Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol Biochem Behav., 1988 Oct. 31(2): p. 455-61.
7. Butler, S.H., et al., A limited arthritic model for chronic pain studies in the rat. Pain, 1992. 48(1): p. 73-81.
8. Woolf, C.J. and R.J. Mannion, Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet, 1999. 353(9168): p. 1959-64.
9. Zimmermann, M., Pathobiology of neuropathic pain. Eur J Pharmacol, 2001. 429(1-3): p. 23-37.
10. Merskey, H., Clarifying definition of neuropathic pain. Pain, 2002. 96(3): p. 408-9.
11. Chaplan, S.R.S., L.S, Agonizing over pain terminology. Pain, 1997. 6: p. 81-87.
12. R, D., Neuronal plasticity and pain following peripheral tissue inflammation or nerve injury. Proceedings of the VIth World Congress on Pain, 1991: p. 263-276.
13. Wang, L.X. and Z.J. Wang, Animal and cellular models of chronic pain. Adv Drug Deliv Rev, 2003. 55(8): p. 949-65.
14. Chaplan, S.R., et al., Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods, 1994. 53(1): p. 55-63.
15. G.J.Bennett, Y.K.X., A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain, 1988. 33: p. 87-107.
16. B.H.Lee, Y.W.Y., K.Chung,J.M.Chung,, Comparison of sympathetic sprouting in sensory ganglia in three animal models of neuropathic pain. Exp.Brain.Res, 1998. 120: p. 432-438.
17. K.Hargreaves, R.D., F.Brown,C.Flores,J.Joris, A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain, 1988. 32: p. 77-88.
18. L.O.Randall, J.J.S., A method for measurement of analgesic activity on inflammed tissue. Arch.Int.Pharmacodyn, 1957. 61: p. 409-419.
19. Bennett, G.J., Neuropathic pain: new insights, new interventions. Hosp Pract (Minneap), 1998. 33(10): p. 95-8, 101-4, 107-10 passim.
20. Wall, P.D., et al., Autotomy following peripheral nerve lesions: experimental anaesthesia dolorosa. Pain, 1979. 7(2): p. 103-11.
21. C.D.Mills, J.J.G., C.E.Hulsebosch, Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury. J.Neurotrauma, 2001. 18: p. 1091-1105.
22. Beric, A., M.R. Dimitrijevic, and U. Lindblom, Central dysesthesia syndrome in spinal cord injury patients. Pain,1988. 34(2): p. 109-16.
23. Cohen, M.J., et al., Comparing chronic pain from spinal cord injury to chronic pain of other origins. Pain, 1988. 35(1): p. 57-63.
24. Yezierski, R.P., Pain following spinal cord injury: the clinical problem and experimental studies. Pain, 1996. 68(2-3): p. 185-94.
25. A.R.Allen, Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal clumn. J.Am.Med.Assoc, 1911. 57: p. 878-880.
26. Tator, C.H., Experimental circumferential compression injury of primate spinal cord. Proc Veterans Adm Spinal Cord Inj Conf, 1971. 18: p. 2-5.
27. Tator, C.H., Acute spinal cord injury in primates produced by an inflatable extradural cuff. Can J Surg, 1973. 16(3): p. 222-31.
28. Tarlov, I.M., Acute spinal cord compression paralysis. J Neurosurg, 1972. 36(1): p. 10-20.
29. A . Bjorklund, R.K., U. Stenevi, K.A.West, Development and growth of axonal sprouts from noradrenaline and 5-hydroxytryptamine neurones in the rat spinal cord,. Brain Res, 1971. 31: p. 21-33.
30. A .S. Rivlin, C.H.T., Regional spinal cord blood flow in rats after severe cord trauma. Neurosurg, 1978. 49: p. 844-853.
31. A .S. Rivlin, C.H.T., Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat,. Surg. Neurol., 1978. 10: p. 38-43.
32. M .D. Christensen, A.W.E., J.T. Pickelman, C.E.Hulsebosch, Mechanical and thermal allodynia in chronic central pain following spinal cord injury,. Pain, 1996. 68: p. 97-107.
33. A .D. Bennett, A.W.E., C.E. Hulsebosch, Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury. Brain Res., 2000. 859: p. 72-82.
34. A .D. Bennett, K.M.C., C.E. Hulsebosch,, Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chronic central pain. Pain, 2000. 86: p. 163-175.
35. Balentine, J.D., Pathology of experimental spinal cord trauma. I. The necrotic lesion as a function of vascular injury. Lab. Invest., 1978. 39: p. 236-253.
36. J . Greenberg, P.E.M., J.D. Balentine, Lysosomal activity in experimental spinal cord trauma: an ultrastructural cytochemical evaluation. Surg. Neurol., 1978. 9: p. 361-364.
37. Anderson, T.E., A controlled pneumatic technique for experimental spinal cord contusion. J. Neurosci. Methods, 1982. 6: p. 327-333.
38. J .X. Hao, X.J.X., H. Aldskogius, A. Seiger, Z. Wiesenfeld Hallin, Allodynia-like effects in rat after ischaemic spinal cord injury photochemically induced by laser irradiation. Pain, 1991. 45: p. 175-185.
39. X J. Xu, J.X.H., H. Aldskogius, A. Seiger, Chronic pain-related syndrome in rats after ischemic spinal cord lesion. Pain, 1992. 48: p. 279-290.
40. R .P. Yezierski, S.H.P., The mechanosensitivity of spinal sensory neurons following intraspinal injections of quisqualic acid in the rat. Neurosci. Lett, 1993. 157: p. 115-119.
41. R .P. Yezierski, Pain following spinal cord injury: pathophysiology and central mechanisms. Prog. Brain Res., 2000. 129(429-449).
42. G.L. Wilcox, Pharmacological studies of grooming and scratching behavior elicited by spinal substance P and excitatory amino acids. Ann. NY Acad. Sci., 1988. 525: p. 228-236.
43. L .M. Aanonsen, G.L.W., Muscimol, gamma-amino-butyric acid A receptors and excitatory amino acids in the mouse spinal cord. J. Pharmacol. Exp. Ther. 248: p. 1034-1038.
44. X .F. Sun, A.A.L., Behavioral sensitization to kainic acid and quisqualic acid in mice: comparison to NMDA and substance P responses. J. Neurosci, 1991. 11: p. 3111-3123.
45. D . Budai, G.L.W., A.A. Larson, Enhancement of NMDA-evoked neuronal activity by glycine in the rat spinal cord in vivo. Neurosci. Lett, 1992. 135: p. 265-268.
46. C .A. Fairbanks, K.L.S., K.L. Brewer, C.G. Yu, Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc. Natl. Acad.Sci. USA, 2000. 97: p. 10584-10589.
47. T .W. Vanderah, T.L., J.M. Lashbrook, M.L. Nichols, Single intrathecal injections of dynorphin A or des-Tyr-clinicallydynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain, 1996. 68: p. 275-281.
48. T .M. Laughlin, T.W.V., J. Lashbrook, M.L. Nichols, Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain, 1997. 72: p. 253-260.
49. A .A. Larson, G.L.W., Synergistic behavioral effects of serotonin and tryptamine injected intrathecally in mice,. Neuropharmacology, 1984. 23: p. 1415-1418.
50. Z . Seltzer, R.D., Y. Shir,, A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury,. Pain, 190. 43: p. 205-218.
51. S .H. Kim, J.M.C., An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain, 1992. 50: p. 355-363.
52. J .A. DeLeo, D.W.C., S. Willenbring, R.W. Colburn,, Characterization of a neuropathic pain model: sciatic cryoneurolysis in the rat. Pain, 1994. 56: p. 9-16.
53. I . Decosterd, A.A., C.J. Woolf, Progressive tactile hypersensitivity after a peripheral nerve crush: non-noxious mechanical stimulus-induced neuropathic pain. Pain, 2002. 100: p.155-162.
54. J .A. DeLeo, R.P.Y., The role of neuroinflammation and neuroimmune activation in persistent pain. Pain,2001. 90: p. 1-6.
55. M . Shimoyama, K.T., F. Hasue, N. Shimoyama,, A mouse model of neuropathic cancer pain. Pain,2002. 99: p. 167-174.
56. R . Amir, M.D., Ongoing activity in neuroma afferents bearing retrograde sprouts. Brain Res, 1993. 630: p. 283-288.
57. N .E. Saade, M.Z.I., S.F. Atweh, S.J. Jabbur, Explosive autotomy induced by simultaneous dorsal column lesion and limb denervation: a possible model for acute deafferentation pain. Exp.Neurol,1993. 119: p. 272-279.
58. N . Attal, F.J., V. Kayser, G. Guilbaud,, Further evidence for 'pain-related' behaviours in a model of unilateral peripheral mononeuropathy. Pain, 1990. 41: p. 235-251.
59. Y . Choi, Y.W.Y., H.S. Na, S.H. Kim, J.M. Chung, Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain, 1994. 59: p. 369-376.
60. B .H. Lee, Y.W.Y., K. Chung, J.M. Chung, Comparison of sympathetic sprouting in sensory ganglia in three animal models of neuropathic pain. Exp.Brain.Res, 1998. 120: p. 432-438.
61. A .B. Malmberg, A.I.B., Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain, 1998. 76: p. 215-222.
62. C . Sommer, M.S., Painful mononeuropathy in C57BL/Wld mice with delayed Wallerian degeneration:differential effects of cytokine production and nerve regene ration on thermal and mechanical hypersensitivity. Brain Res, 1998. 784: p. 154-162.
63. Z . Wang, L.R.G., M.H. Ossipov, T.W. Vanderah, M.B.Brennan, U. Hochgeschwender,V.J. Hruby, T.P. Malan Jr., Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J. Neurosci, 2001. 21: p. 1779-1786.
64. R . Wagner, J.A.D., D.W. Coombs, Spinal dynorphin immunoreactivity increases bilaterally in a neuropathic pain model. Brain Res, 1993. 629: p. 323-326.
65. S . Willenbring, I.G.B., J.A. DeLeo, cryoneurolysis in rats: a model of sympathetically independent pain. Part 1: Effects of sympathectomy. Anesth. Analg, 1995. 81: p. 544-548.
66. S .K. Back, B.S., S.K. Hong, H.S. Na, A mouse model for peripheral neuropathy produced by a partial injury of the nerve supplying the tail. Neurosci. Lett., 2002. 322: p.153-156.
67. G.Said, M.H.-J. , Nerve lesions induced by macrophage activation. Res. Immunol., 1992. 143: p. 589-599.
68. M . Chacur, E.D.M., L.S. Gazda, C. Armstrong,, A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain,2001. 94: p.231-244.
69. T .J. Maves, P.S.P., G.F. Gebhart, S.T. Meller, Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in man. Pain, 1993. 54: p. 57-69.
70. E . Eliav, U.H., M.A. Ruda, G.J. Bennett,, Neuropathic pain from an experimental neuritis of the rat sciatic nerve. Pain, 1999. 83(169-182).
71. CJ, I.D.W., Spared nerve injury: an animal model of persistent peripheral neuropathie pain. Pain, 2000. 87: p. 149-158.
72. Z . Simmons, E.L.F., Update on diabetic neuropathy. Curr. Opin. Neurol., 2002. 15: p. 595-603.
73. P J. Dyck, K.M.K., J.L. Karnes, W.J. Litchy, R. Klein, The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology, 1993. 43: p.817-824.
74. M .C. Rowbotham, H.L.F., The relationship of pain,allodynia and thermal sensation in post-herpetic neuralgia,. Brain Res, 1996. 119: p. 347-354.
75. C . Sadzot-Delvaux, S.D., A. Nikkels, J. Piette, Varicella-zoster virus latency in the adult rat is a useful model for human latent infection. Neurology, 1995. 45: p. s18-20.
76. C . Courteix, M.B., C. Chantelauze, J. Lavarenne,, Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain, 1994. 57: p. 153-160.
77. C . Courteix, A.E., J. Lavarenne, Streptozocin-in-duced diabetic rats: behavioural evidence for a model of chronic pain. Pain, 1993. 53: p. 81-88.
78. Sima, A.A., Peripheral neuropathy in the spontaneously diabetic BB-Wistar-rat. An ultrastructural study, Acta Neuropathol, 1980. 51: p. 223-227.
79. R . Mosseri, T.W., M. Shefi, E. Shafrir, J. Meyerovitch, Gluconeogenesis in non-obese diabetic (NOD) mice: in vivo effects of vandadate treatment on hepatic glucose-6-phosphatase and phosphoenolpyruvate carboxykinase. Metabolism, 2000. 49: p. 321-325.
80. N . Takeshita, I.Y., Antinociceptive effects of morphine were different between experimental and genetic diabetes. Pharmacol. Biochem. Behav., 1998. 60: p. 889-897.
81. E . Shafrir, S.S., I. Nachliel, M. Khamaisi, Treatment of diabetes with vanadium salts:general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil. Diabetes Metab.Res. Rev., 2001. 17: p. 55-56.
82. Bridges, D., Thompson,S.W.N.and Rice, A.S.C, Mechanisms of neuropathic pain.Br J Anaesth. Br J Anaesth, 2001. 87: p. 12-26.
83. Mao J, P.D., Mayer DJ, Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain, 1995. 62(3): p. 259-274.
84. Portenoy RK, L.P., Management of cancer pain. Lancet, 1999. 353: p. 1695-1700.
85. Meuser T, P.C., Radbruch L, et al, Symptoms during cancer pain treatment following WHO guidelines : a longitudinal follow up study of symptom prevalence,severity and etiology. Pain, 2001. 93: p. 247-257.
86. Banning, A., P. Sjogren, and H. Henriksen, Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain, 1991. 45(1): p. 45-8.
87. Vecht, C.J., Cancer pain: a neurological perspective. Curr.Opin. Neurol., 2000. 13: p. 649-653.
88. S . Quasthoff, H.P.H., Chemotherapy-induced peripheral neuropathy. J. Neurol., 2002. 249: p. 9-17.
89. K .D. Tanner, D.B.R., J.D. Levine, Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J. Neurosci., 1998. 18: p. 6480-6491.
90. N . Authier, F.C., A. Eschalier, J. Fialip, Pain related behaviour during vincristine-induced neuropathy in rats. Neuroreport, 1999. 10: p. 965-968.
91. N . Nozaki-Taguchi, S.R.C., E.S. Higuera,et al, Vincristine-induced allodynia in the rat. Pain, 2001.93: p. 69-76.
92. Y . Mimura, H.K., K. Eguchi, T. Ogawa,, Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology, 2000. 21: p. 513-520.
93. G. Cavaletti, G.T., M. Braga, S. Tazzari, Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp. Neurol, 1995. 133: p. 64-72.
94. O .A. Dina, X.C., D. Reichling, J.D. Levine, Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience, 2001. 108: p. 507-515.
95. D . Strumberg, S.B., M.W. Korn, S. Koeppen, J. Ranft et al, Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann. Oncol., 2002. 13: p. 229-236.
96. E .S. McDonald, A.J.W., Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol.Dis., 2002. 9: p. 220-233.
97. N . Authier, J.F., A. Eschalier, F. Coudore,, Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci. Lett, 2000. 291: p. 73-76.
98. P .F. Pradat, P.K., S. Naimi-Sadaoui, F. Finiels et al, Viral and non-viral gene therapy partially prevents experimental cisplatin-induced neuropathy. Gene Ther, 2002. 9: p. 1333-1337.
99. L .A. Martin, N.A.H., Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies J. Pain Symptom Manage, 1997. 14: p. 99-117.
100. S . Mercadante, Malignant bone pain: pathophysiology and treatment. Pain, 1997. 69: p. 1-18.
101. Pecherstorfer M, V.M., Diagnosis and monitoring of bone metastases: clinical means. In: Body JJ, ed. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, Inc, 2000: p. 97-129.
102. Preston D, B.K., Schiefelbein M, Spicer J, Palliation of painful bone metastases: radioactive isotopes. In: Body JJ, ed. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, Inc, 2000: p. 287-304.
103. Mercadante, S. and E. Arcuri, Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev, 1998. 24(6): p. 425-32.
104. Portenoy, R.K. and N.A. Hagen, Breakthrough pain: definition, prevalence and characteristics. Pain, 1990. 41(3): p. 273-81.
105. Mercadante, S., Malignant bone pain: pathophysiology and treatment. Pain, 1997. 69(1-2): p. 1-18.
106. Mercadante, S., Controversies over spinal treatment in advanced cancer patients. Support Care Cancer, 1998. 6(6): p. 495-502.
107. Luger, N.M., et al., Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res, 2001. 61(10): p. 4038-47.
108. Schwei, M.J., et al., Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci, 1999. 19(24): p. 10886-97.
109. Honore, P., et al., Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog Brain Res, 2000. 129: p. 389-97.
110. Honore, P., et al., Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med, 2000. 6(5): p. 521-8.
111. N .M. Luger, M.A.S., M.J. Schwei, D.B. Mach, et al, Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer versus inflammatory pain. Pain, 2002. 99: p. 397-406.
112. P .W. Wacnik, L.J.E., T.R. Ruggles, et al, Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J. Neurosci., 2001. 21: p. 9355-9366.
113. al, W.P.W.E.m.U.R.T.R.e., Functional interaction between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of anew marine model of canfer pain. Neurosci, 2001. 21: p. 9355-9366.
114. Walker, K., et al., Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain, 2002. 100(3): p. 219-29.
115. Sabino, M.A., et al., Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res, 2002. 62(24): p. 7343-9.
116. Wacnik PW, E.L., Ruggles TR , et al., Functional interactions between tumor and peripheral nerve:morphology , algogen identification and behavioral characterization of a new murine model of cancer pain. J Neurosci, 2001. 21: p. 9355-9366.
117. Clohisy, D.R. and P.W. Mantyh, Bone cancer pain. Clin Orthop Relat Res, 2003(415 Suppl): p. S279-88.
118. Clohisy, D.R., S.L. Perkins, and M.L. Ramnaraine, Review of cellular mechanisms of tumor osteolysis. Clin Orthop Relat Res, 2000(373): p. 104-14.
119. Honore, P., et al., Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience, 2000. 98(3): p. 585-98.
120. Fukamachi, S., et al., Altered expressions of glutamate transporter subtypes in rat model of neonatal cerebral hypoxia-ischemia. Brain Res Dev Brain Res, 2001. 132(2): p. 131-9.
121. Sabino, M.A., et al., Tooth extraction-induced internalization of the substance P receptor in trigeminal nucleus and spinal cord neurons: imaging the neurochemistry of dental pain. Pain, 2002. 95(1-2): p. 175-86.
122. O'Connell, J.X., et al., Osteoid osteoma: the uniquely innervated bone tumor. Mod Pathol, 1998. 11(2): p. 175-80.
123. Shir, Y., et al., Correlation of intact sensibility and neuropathic pain-related behaviors in eight inbred and outbred rat strains and selection lines. Pain, 2001. 90(1-2): p. 75-82.
2. Portenoy RK, L.P., Management of cancer pain. Lancet,1999. 353: p. 1695-1700.
3. Meuser T, P.C., Radbruch L , et al, Symptoms during cancer pain treatment following WHO guidelines : a longitudinal follow up study of symptom prevalence,severity and etiology. Pain, 2001. 93: p. 247-257.
4. Banning, A., P. Sjogren, and H. Henriksen, Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain,1991. 45(1): p. 45-8.
5. Coleman, R.E., Skeletal complications of malignancy. Cancer, 1997. 80(8 Suppl): p. 1588-94.
6. Thurlimann, B. and N.D. de Stoutz, Causes and treatment of bone pain of malignant origin. Drugs, 1996. 51(3): p. 383-98.
7. S . Mercadante, Malignant bone pain: pathophysiology and treatment. Pain, 1997. 69: p. 1-18.
8. Pecherstorfer M, V.M., Diagnosis and monitoring of bone metastases: clinical means. In: Body JJ, ed. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, Inc, 2000: p. 97-129.
9. Preston D, B.K., Schiefelbein M, Spicer J, Palliation of painful bone metastases: radioactive isotopes. In: Body JJ, ed. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, Inc, 2000: p. 287-304.
10. Mercadante, S. and E. Arcuri, Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev, 1998. 24(6): p. 425-32.
11. Portenoy, R.K. and N.A. Hagen, Breakthrough pain: definition, prevalence and characteristics. Pain, 1990. 41(3): p. 273-81.
12. Mercadante, S., Malignant bone pain: pathophysiology and treatment. Pain, 1997. 69(1-2): p. 1-18.
13. Mercadante, S., Controversies over spinal treatment in advanced cancer patients. Support Care Cancer, 1998. 6(6): p. 495-502.
14. Portenoy, R.K., D. Payne, and P. Jacobsen, Breakthrough pain: characteristics and impact in patients with cancer pain. Pain, 1999. 81(1-2): p. 129-34.
15. Luger, N.M., et al., Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res, 2001. 61(10): p. 4038-47.
16. SD, S.M.H.P.R., Neurochemical and cellular reorganization of the spinal cord in a marine model of bone cancer pain. Neurosci, 1999. 19: p. 10886-10897.
17. al, W.P.E.m.U.R.T.e., Functional interaction between tumor and peripheral nerveFunctional interaction between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new marine model of canfer pain. Neurosci,2001. 21: p. 9355-9366.
18. Wacnik, P.W., et al., Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular Carrageenan. Pain, 2003. 101(1-2): p. 175-86.
19. Vivancos, G.G., et al., An electronic pressure-meter nociception paw test for rats. Braz J Med Biol Res, 2004. 37(3): p. 391-9.
20. Fan WK, Q.Z., Biologic characteristics of a transplantable hepatoma inbred 615 mice (H615). [A].Tang ZY. Primary Liver Cancer[M].Berlin: SpringerVerlag, Beijing: China Academic Publishes, 1989: p. 98-108.
21. Hirohashi, S., et al., Production of alpha-fetoprotein and normal serum proteins by xenotransplanted human hepatomas in relation to their growth and morphology. Cancer Res, 1979. 39(5): p. 1819-28.
22. Z . Seltzer, R.D., Y. Shir,, A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury,. Pain, 190. 43: p. 205-218.
23. Stein C, M.M., Herz A, Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol Biochem Behav., 1988 Oct. 31(2): p. 455-61.
24. Levitt, M. and J.H. Levitt, The deafferentation syndrome in monkeys: dysesthesias of spinal origin. Pain, 1981. 10(2): p. 129-47.
25. Kirk, E.J. and D. Denny-Brown, Functional variation in dermatomes in the macaque monkey following dorsal root lesions. J Comp Neurol,1970. 139(3): p. 307-20.
26. Carlton, S.M., et al., Behavioral manifestations of an experimental model for peripheral neuropathy produced by spinal nerve ligation in the primate. Pain, 1994. 56(2): p. 155-66.
27. Ford, R.W., A reproducible spinal cord injury model in the cat. J Neurosurg, 1983. 59(2): p. 268-75.
28. Hylden, J.L., et al., Descending serotonergic fibers in the dorsolateral and ventral funiculi of cat spinal cord. Neurosci Lett, 1985. 62(3): p. 299-304.
29. Butler, S.H., et al., A limited arthritic model for chronic pain studies in the rat. Pain, 1992. 48(1): p. 73-81.
30. Woolf, C.J. and R.J. Mannion, Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet, 1999. 353(9168): p. 1959-64.
31. Zimmermann, M., Pathobiology of neuropathic pain. Eur J Pharmacol, 2001. 429(1-3): p. 23-37.
32. Dornelas, C.A., et al., [Experimental model of Walker 256 carcinosarcoma in rats bladder]. Acta Cir Bras, 2006. 21(1): p. 38-42.
33. Buffon, A., et al., Diminution in adenine nucleotide hydrolysis by platelets and serum from rats submitted to Walker 256 tumour. Mol Cell Biochem, 2006. 281(1-2): p. 189-95.
1. Levitt, M. and J.H. Levitt, The deafferentation syndrome in monkeys: dysesthesias of spinal origin. Pain, 1981. 10(2): p. 129-47.
2. Kirk, E.J. and D. Denny-Brown, Functional variation in dermatomes in the macaque monkey following dorsal root lesions. J Comp Neurol, 1970.139(3): p. 307-20.
3. Carlton, S.M., et al., Behavioral manifestations of an experimental model for peripheral neuropathy produced by spinal nerve ligation in the primate. Pain, 1994. 56(2): p. 155-66.
4. Ford, R.W., A reproducible spinal cord injury model in the cat. J Neurosurg, 1983. 59(2): p. 268-75.
5. Hylden, J.L., et al., Descending serotonergic fibers in the dorsolateral and ventral funiculi of cat spinal cord. Neurosci Lett, 1985. 62(3): p. 299-304.
6. Stein C, M.M., Herz A, Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol Biochem Behav., 1988 Oct. 31(2): p. 455-61.
7. Butler, S.H., et al., A limited arthritic model for chronic pain studies in the rat. Pain, 1992. 48(1): p. 73-81.
8. Woolf, C.J. and R.J. Mannion, Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet, 1999. 353(9168): p. 1959-64.
9. Zimmermann, M., Pathobiology of neuropathic pain. Eur J Pharmacol, 2001. 429(1-3): p. 23-37.
10. Merskey, H., Clarifying definition of neuropathic pain. Pain, 2002. 96(3): p. 408-9.
11. Chaplan, S.R.S., L.S, Agonizing over pain terminology. Pain, 1997. 6: p. 81-87.
12. R, D., Neuronal plasticity and pain following peripheral tissue inflammation or nerve injury. Proceedings of the VIth World Congress on Pain, 1991: p. 263-276.
13. Wang, L.X. and Z.J. Wang, Animal and cellular models of chronic pain. Adv Drug Deliv Rev, 2003. 55(8): p. 949-65.
14. Chaplan, S.R., et al., Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods, 1994. 53(1): p. 55-63.
15. G.J.Bennett, Y.K.X., A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain, 1988. 33: p. 87-107.
16. B.H.Lee, Y.W.Y., K.Chung,J.M.Chung,, Comparison of sympathetic sprouting in sensory ganglia in three animal models of neuropathic pain. Exp.Brain.Res, 1998. 120: p. 432-438.
17. K.Hargreaves, R.D., F.Brown,C.Flores,J.Joris, A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain, 1988. 32: p. 77-88.
18. L.O.Randall, J.J.S., A method for measurement of analgesic activity on inflammed tissue. Arch.Int.Pharmacodyn, 1957. 61: p. 409-419.
19. Bennett, G.J., Neuropathic pain: new insights, new interventions. Hosp Pract (Minneap), 1998. 33(10): p. 95-8, 101-4, 107-10 passim.
20. Wall, P.D., et al., Autotomy following peripheral nerve lesions: experimental anaesthesia dolorosa. Pain, 1979. 7(2): p. 103-11.
21. C.D.Mills, J.J.G., C.E.Hulsebosch, Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury. J.Neurotrauma, 2001. 18: p. 1091-1105.
22. Beric, A., M.R. Dimitrijevic, and U. Lindblom, Central dysesthesia syndrome in spinal cord injury patients. Pain,1988. 34(2): p. 109-16.
23. Cohen, M.J., et al., Comparing chronic pain from spinal cord injury to chronic pain of other origins. Pain, 1988. 35(1): p. 57-63.
24. Yezierski, R.P., Pain following spinal cord injury: the clinical problem and experimental studies. Pain, 1996. 68(2-3): p. 185-94.
25. A.R.Allen, Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal clumn. J.Am.Med.Assoc, 1911. 57: p. 878-880.
26. Tator, C.H., Experimental circumferential compression injury of primate spinal cord. Proc Veterans Adm Spinal Cord Inj Conf, 1971. 18: p. 2-5.
27. Tator, C.H., Acute spinal cord injury in primates produced by an inflatable extradural cuff. Can J Surg, 1973. 16(3): p. 222-31.
28. Tarlov, I.M., Acute spinal cord compression paralysis. J Neurosurg, 1972. 36(1): p. 10-20.
29. A . Bjorklund, R.K., U. Stenevi, K.A.West, Development and growth of axonal sprouts from noradrenaline and 5-hydroxytryptamine neurones in the rat spinal cord,. Brain Res, 1971. 31: p. 21-33.
30. A .S. Rivlin, C.H.T., Regional spinal cord blood flow in rats after severe cord trauma. Neurosurg, 1978. 49: p. 844-853.
31. A .S. Rivlin, C.H.T., Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat,. Surg. Neurol., 1978. 10: p. 38-43.
32. M .D. Christensen, A.W.E., J.T. Pickelman, C.E.Hulsebosch, Mechanical and thermal allodynia in chronic central pain following spinal cord injury,. Pain, 1996. 68: p. 97-107.
33. A .D. Bennett, A.W.E., C.E. Hulsebosch, Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury. Brain Res., 2000. 859: p. 72-82.
34. A .D. Bennett, K.M.C., C.E. Hulsebosch,, Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chronic central pain. Pain, 2000. 86: p. 163-175.
35. Balentine, J.D., Pathology of experimental spinal cord trauma. I. The necrotic lesion as a function of vascular injury. Lab. Invest., 1978. 39: p. 236-253.
36. J . Greenberg, P.E.M., J.D. Balentine, Lysosomal activity in experimental spinal cord trauma: an ultrastructural cytochemical evaluation. Surg. Neurol., 1978. 9: p. 361-364.
37. Anderson, T.E., A controlled pneumatic technique for experimental spinal cord contusion. J. Neurosci. Methods, 1982. 6: p. 327-333.
38. J .X. Hao, X.J.X., H. Aldskogius, A. Seiger, Z. Wiesenfeld Hallin, Allodynia-like effects in rat after ischaemic spinal cord injury photochemically induced by laser irradiation. Pain, 1991. 45: p. 175-185.
39. X J. Xu, J.X.H., H. Aldskogius, A. Seiger, Chronic pain-related syndrome in rats after ischemic spinal cord lesion. Pain, 1992. 48: p. 279-290.
40. R .P. Yezierski, S.H.P., The mechanosensitivity of spinal sensory neurons following intraspinal injections of quisqualic acid in the rat. Neurosci. Lett, 1993. 157: p. 115-119.
41. R .P. Yezierski, Pain following spinal cord injury: pathophysiology and central mechanisms. Prog. Brain Res., 2000. 129(429-449).
42. G.L. Wilcox, Pharmacological studies of grooming and scratching behavior elicited by spinal substance P and excitatory amino acids. Ann. NY Acad. Sci., 1988. 525: p. 228-236.
43. L .M. Aanonsen, G.L.W., Muscimol, gamma-amino-butyric acid A receptors and excitatory amino acids in the mouse spinal cord. J. Pharmacol. Exp. Ther. 248: p. 1034-1038.
44. X .F. Sun, A.A.L., Behavioral sensitization to kainic acid and quisqualic acid in mice: comparison to NMDA and substance P responses. J. Neurosci, 1991. 11: p. 3111-3123.
45. D . Budai, G.L.W., A.A. Larson, Enhancement of NMDA-evoked neuronal activity by glycine in the rat spinal cord in vivo. Neurosci. Lett, 1992. 135: p. 265-268.
46. C .A. Fairbanks, K.L.S., K.L. Brewer, C.G. Yu, Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc. Natl. Acad.Sci. USA, 2000. 97: p. 10584-10589.
47. T .W. Vanderah, T.L., J.M. Lashbrook, M.L. Nichols, Single intrathecal injections of dynorphin A or des-Tyr-clinicallydynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain, 1996. 68: p. 275-281.
48. T .M. Laughlin, T.W.V., J. Lashbrook, M.L. Nichols, Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain, 1997. 72: p. 253-260.
49. A .A. Larson, G.L.W., Synergistic behavioral effects of serotonin and tryptamine injected intrathecally in mice,. Neuropharmacology, 1984. 23: p. 1415-1418.
50. Z . Seltzer, R.D., Y. Shir,, A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury,. Pain, 190. 43: p. 205-218.
51. S .H. Kim, J.M.C., An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain, 1992. 50: p. 355-363.
52. J .A. DeLeo, D.W.C., S. Willenbring, R.W. Colburn,, Characterization of a neuropathic pain model: sciatic cryoneurolysis in the rat. Pain, 1994. 56: p. 9-16.
53. I . Decosterd, A.A., C.J. Woolf, Progressive tactile hypersensitivity after a peripheral nerve crush: non-noxious mechanical stimulus-induced neuropathic pain. Pain, 2002. 100: p.155-162.
54. J .A. DeLeo, R.P.Y., The role of neuroinflammation and neuroimmune activation in persistent pain. Pain,2001. 90: p. 1-6.
55. M . Shimoyama, K.T., F. Hasue, N. Shimoyama,, A mouse model of neuropathic cancer pain. Pain,2002. 99: p. 167-174.
56. R . Amir, M.D., Ongoing activity in neuroma afferents bearing retrograde sprouts. Brain Res, 1993. 630: p. 283-288.
57. N .E. Saade, M.Z.I., S.F. Atweh, S.J. Jabbur, Explosive autotomy induced by simultaneous dorsal column lesion and limb denervation: a possible model for acute deafferentation pain. Exp.Neurol,1993. 119: p. 272-279.
58. N . Attal, F.J., V. Kayser, G. Guilbaud,, Further evidence for 'pain-related' behaviours in a model of unilateral peripheral mononeuropathy. Pain, 1990. 41: p. 235-251.
59. Y . Choi, Y.W.Y., H.S. Na, S.H. Kim, J.M. Chung, Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain, 1994. 59: p. 369-376.
60. B .H. Lee, Y.W.Y., K. Chung, J.M. Chung, Comparison of sympathetic sprouting in sensory ganglia in three animal models of neuropathic pain. Exp.Brain.Res, 1998. 120: p. 432-438.
61. A .B. Malmberg, A.I.B., Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain, 1998. 76: p. 215-222.
62. C . Sommer, M.S., Painful mononeuropathy in C57BL/Wld mice with delayed Wallerian degeneration:differential effects of cytokine production and nerve regene ration on thermal and mechanical hypersensitivity. Brain Res, 1998. 784: p. 154-162.
63. Z . Wang, L.R.G., M.H. Ossipov, T.W. Vanderah, M.B.Brennan, U. Hochgeschwender,V.J. Hruby, T.P. Malan Jr., Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J. Neurosci, 2001. 21: p. 1779-1786.
64. R . Wagner, J.A.D., D.W. Coombs, Spinal dynorphin immunoreactivity increases bilaterally in a neuropathic pain model. Brain Res, 1993. 629: p. 323-326.
65. S . Willenbring, I.G.B., J.A. DeLeo, cryoneurolysis in rats: a model of sympathetically independent pain. Part 1: Effects of sympathectomy. Anesth. Analg, 1995. 81: p. 544-548.
66. S .K. Back, B.S., S.K. Hong, H.S. Na, A mouse model for peripheral neuropathy produced by a partial injury of the nerve supplying the tail. Neurosci. Lett., 2002. 322: p.153-156.
67. G.Said, M.H.-J. , Nerve lesions induced by macrophage activation. Res. Immunol., 1992. 143: p. 589-599.
68. M . Chacur, E.D.M., L.S. Gazda, C. Armstrong,, A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain,2001. 94: p.231-244.
69. T .J. Maves, P.S.P., G.F. Gebhart, S.T. Meller, Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in man. Pain, 1993. 54: p. 57-69.
70. E . Eliav, U.H., M.A. Ruda, G.J. Bennett,, Neuropathic pain from an experimental neuritis of the rat sciatic nerve. Pain, 1999. 83(169-182).
71. CJ, I.D.W., Spared nerve injury: an animal model of persistent peripheral neuropathie pain. Pain, 2000. 87: p. 149-158.
72. Z . Simmons, E.L.F., Update on diabetic neuropathy. Curr. Opin. Neurol., 2002. 15: p. 595-603.
73. P J. Dyck, K.M.K., J.L. Karnes, W.J. Litchy, R. Klein, The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology, 1993. 43: p.817-824.
74. M .C. Rowbotham, H.L.F., The relationship of pain,allodynia and thermal sensation in post-herpetic neuralgia,. Brain Res, 1996. 119: p. 347-354.
75. C . Sadzot-Delvaux, S.D., A. Nikkels, J. Piette, Varicella-zoster virus latency in the adult rat is a useful model for human latent infection. Neurology, 1995. 45: p. s18-20.
76. C . Courteix, M.B., C. Chantelauze, J. Lavarenne,, Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain, 1994. 57: p. 153-160.
77. C . Courteix, A.E., J. Lavarenne, Streptozocin-in-duced diabetic rats: behavioural evidence for a model of chronic pain. Pain, 1993. 53: p. 81-88.
78. Sima, A.A., Peripheral neuropathy in the spontaneously diabetic BB-Wistar-rat. An ultrastructural study, Acta Neuropathol, 1980. 51: p. 223-227.
79. R . Mosseri, T.W., M. Shefi, E. Shafrir, J. Meyerovitch, Gluconeogenesis in non-obese diabetic (NOD) mice: in vivo effects of vandadate treatment on hepatic glucose-6-phosphatase and phosphoenolpyruvate carboxykinase. Metabolism, 2000. 49: p. 321-325.
80. N . Takeshita, I.Y., Antinociceptive effects of morphine were different between experimental and genetic diabetes. Pharmacol. Biochem. Behav., 1998. 60: p. 889-897.
81. E . Shafrir, S.S., I. Nachliel, M. Khamaisi, Treatment of diabetes with vanadium salts:general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil. Diabetes Metab.Res. Rev., 2001. 17: p. 55-56.
82. Bridges, D., Thompson,S.W.N.and Rice, A.S.C, Mechanisms of neuropathic pain.Br J Anaesth. Br J Anaesth, 2001. 87: p. 12-26.
83. Mao J, P.D., Mayer DJ, Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain, 1995. 62(3): p. 259-274.
84. Portenoy RK, L.P., Management of cancer pain. Lancet, 1999. 353: p. 1695-1700.
85. Meuser T, P.C., Radbruch L, et al, Symptoms during cancer pain treatment following WHO guidelines : a longitudinal follow up study of symptom prevalence,severity and etiology. Pain, 2001. 93: p. 247-257.
86. Banning, A., P. Sjogren, and H. Henriksen, Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain, 1991. 45(1): p. 45-8.
87. Vecht, C.J., Cancer pain: a neurological perspective. Curr.Opin. Neurol., 2000. 13: p. 649-653.
88. S . Quasthoff, H.P.H., Chemotherapy-induced peripheral neuropathy. J. Neurol., 2002. 249: p. 9-17.
89. K .D. Tanner, D.B.R., J.D. Levine, Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J. Neurosci., 1998. 18: p. 6480-6491.
90. N . Authier, F.C., A. Eschalier, J. Fialip, Pain related behaviour during vincristine-induced neuropathy in rats. Neuroreport, 1999. 10: p. 965-968.
91. N . Nozaki-Taguchi, S.R.C., E.S. Higuera,et al, Vincristine-induced allodynia in the rat. Pain, 2001.93: p. 69-76.
92. Y . Mimura, H.K., K. Eguchi, T. Ogawa,, Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology, 2000. 21: p. 513-520.
93. G. Cavaletti, G.T., M. Braga, S. Tazzari, Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp. Neurol, 1995. 133: p. 64-72.
94. O .A. Dina, X.C., D. Reichling, J.D. Levine, Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience, 2001. 108: p. 507-515.
95. D . Strumberg, S.B., M.W. Korn, S. Koeppen, J. Ranft et al, Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann. Oncol., 2002. 13: p. 229-236.
96. E .S. McDonald, A.J.W., Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol.Dis., 2002. 9: p. 220-233.
97. N . Authier, J.F., A. Eschalier, F. Coudore,, Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci. Lett, 2000. 291: p. 73-76.
98. P .F. Pradat, P.K., S. Naimi-Sadaoui, F. Finiels et al, Viral and non-viral gene therapy partially prevents experimental cisplatin-induced neuropathy. Gene Ther, 2002. 9: p. 1333-1337.
99. L .A. Martin, N.A.H., Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies J. Pain Symptom Manage, 1997. 14: p. 99-117.
100. S . Mercadante, Malignant bone pain: pathophysiology and treatment. Pain, 1997. 69: p. 1-18.
101. Pecherstorfer M, V.M., Diagnosis and monitoring of bone metastases: clinical means. In: Body JJ, ed. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, Inc, 2000: p. 97-129.
102. Preston D, B.K., Schiefelbein M, Spicer J, Palliation of painful bone metastases: radioactive isotopes. In: Body JJ, ed. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, Inc, 2000: p. 287-304.
103. Mercadante, S. and E. Arcuri, Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev, 1998. 24(6): p. 425-32.
104. Portenoy, R.K. and N.A. Hagen, Breakthrough pain: definition, prevalence and characteristics. Pain, 1990. 41(3): p. 273-81.
105. Mercadante, S., Malignant bone pain: pathophysiology and treatment. Pain, 1997. 69(1-2): p. 1-18.
106. Mercadante, S., Controversies over spinal treatment in advanced cancer patients. Support Care Cancer, 1998. 6(6): p. 495-502.
107. Luger, N.M., et al., Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res, 2001. 61(10): p. 4038-47.
108. Schwei, M.J., et al., Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci, 1999. 19(24): p. 10886-97.
109. Honore, P., et al., Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog Brain Res, 2000. 129: p. 389-97.
110. Honore, P., et al., Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med, 2000. 6(5): p. 521-8.
111. N .M. Luger, M.A.S., M.J. Schwei, D.B. Mach, et al, Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer versus inflammatory pain. Pain, 2002. 99: p. 397-406.
112. P .W. Wacnik, L.J.E., T.R. Ruggles, et al, Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J. Neurosci., 2001. 21: p. 9355-9366.
113. al, W.P.W.E.m.U.R.T.R.e., Functional interaction between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of anew marine model of canfer pain. Neurosci, 2001. 21: p. 9355-9366.
114. Walker, K., et al., Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain, 2002. 100(3): p. 219-29.
115. Sabino, M.A., et al., Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res, 2002. 62(24): p. 7343-9.
116. Wacnik PW, E.L., Ruggles TR , et al., Functional interactions between tumor and peripheral nerve:morphology , algogen identification and behavioral characterization of a new murine model of cancer pain. J Neurosci, 2001. 21: p. 9355-9366.
117. Clohisy, D.R. and P.W. Mantyh, Bone cancer pain. Clin Orthop Relat Res, 2003(415 Suppl): p. S279-88.
118. Clohisy, D.R., S.L. Perkins, and M.L. Ramnaraine, Review of cellular mechanisms of tumor osteolysis. Clin Orthop Relat Res, 2000(373): p. 104-14.
119. Honore, P., et al., Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience, 2000. 98(3): p. 585-98.
120. Fukamachi, S., et al., Altered expressions of glutamate transporter subtypes in rat model of neonatal cerebral hypoxia-ischemia. Brain Res Dev Brain Res, 2001. 132(2): p. 131-9.
121. Sabino, M.A., et al., Tooth extraction-induced internalization of the substance P receptor in trigeminal nucleus and spinal cord neurons: imaging the neurochemistry of dental pain. Pain, 2002. 95(1-2): p. 175-86.
122. O'Connell, J.X., et al., Osteoid osteoma: the uniquely innervated bone tumor. Mod Pathol, 1998. 11(2): p. 175-80.
123. Shir, Y., et al., Correlation of intact sensibility and neuropathic pain-related behaviors in eight inbred and outbred rat strains and selection lines. Pain, 2001. 90(1-2): p. 75-82.